

Diego Ferone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3070760/publications.pdf>

Version: 2024-02-01

263
papers

12,877
citations

19608

61
h-index

30848

102
g-index

286
all docs

286
docs citations

286
times ranked

8763
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. <i>Endocrine Reviews</i> , 2004, 25, 102-152.	8.9	1,093
2	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. <i>Annals of Oncology</i> , 2015, 26, 1604-1620.	0.6	514
3	ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2016, 103, 119-124.	1.2	380
4	Persistence of Increased Cardiovascular Risk in Patients with Cushing's Disease after Five Years of Successful Cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2664-2672.	1.8	344
5	Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma. <i>Neuroendocrinology</i> , 2006, 84, 183-188.	1.2	248
6	Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2452-2462.	1.8	246
7	Long-Term Effects of Depot Long-Acting Somatostatin Analog Octreotide on Hormone Levels and Tumor Mass in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2779-2786.	1.8	242
8	ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2016, 103, 139-143.	1.2	241
9	Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 876-883.	1.8	219
10	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e937-e946.	1.8	207
11	Effect of Octreotide Pretreatment on Surgical Outcome in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3308-3314.	1.8	199
12	Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. <i>Endocrine-Related Cancer</i> , 2017, 24, 505-518.	1.6	164
13	Systemic Hypertension and Impaired Glucose Tolerance Are Independently Correlated to the Severity of the Acromegalic Cardiomyopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 193-199.	1.8	154
14	Effect of Different Dopaminergic Agents in the Treatment of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 518-523.	1.8	140
15	Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 2777-2781.	1.8	130
16	Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E66-E71.	1.8	129
17	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. <i>Neuroendocrinology</i> , 2017, 105, 201-211.	1.2	127
18	Prediction of efficacy of octreotide therapy in patients with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2356-2362.	1.8	126

#	ARTICLE	IF	CITATIONS
19	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2017, 105, 245-254.	1.2	122
20	Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. <i>Acta Diabetologica</i> , 2009, 46, 85-95.	1.2	119
21	Effects of 1-Year Treatment with Octreotide on Cardiac Performance in Patients with Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 17-23.	1.8	115
22	Novel insights in dopamine receptor physiology. <i>European Journal of Endocrinology</i> , 2007, 156, S13-S21.	1.9	114
23	Correlation of in Vitro and in Vivo Somatotrophic Adenoma Responsiveness to Somatostatin Analogs and Dopamine Agonists with Immunohistochemical Evaluation of Somatostatin and Dopamine Receptors and Electron Microscopy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 1412-1417.	1.8	114
24	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. <i>European Journal of Endocrinology</i> , 2015, 172, R227-R239.	1.9	114
25	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3231-3244.	1.8	113
26	Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. <i>European Journal of Endocrinology</i> , 1998, 138, 286-293.	1.9	111
27	Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 77, 790-793.	1.8	105
28	Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumours: Well-Differentiated Colon and Rectum Tumour/Carcinoma. <i>Neuroendocrinology</i> , 2008, 87, 31-39.	1.2	104
29	Overexpression of Stromal Cell-Derived Factor 1 and Its Receptor CXCR4 Induces Autocrine/Paracrine Cell Proliferation in Human Pituitary Adenomas. <i>Clinical Cancer Research</i> , 2008, 14, 5022-5032.	3.2	104
30	Peptide receptor therapies in neuroendocrine tumors. <i>Journal of Endocrinological Investigation</i> , 2009, 32, 360-369.	1.8	104
31	Is the Acromegalic Cardiomyopathy Reversible? Effect of 5-Year Normalization of Growth Hormone and Insulin-Like Growth Factor I Levels on Cardiac Performance*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1551-1557.	1.8	102
32	Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. <i>Clinical Endocrinology</i> , 2001, 54, 515-524.	1.2	101
33	Two-Year Follow-Up of Acromegalic Patients Treated with Slow Release Lanreotide (30 mg)1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4099-4103.	1.8	99
34	In Vitro Characterization of Somatostatin Receptors in the Human Thymus and Effects of Somatostatin and Octreotide on Cultured Thymic Epithelial Cells. <i>Endocrinology</i> , 1999, 140, 373-380.	1.4	95
35	Cardiovascular Effects of Depot Long-Acting Somatostatin Analog Sandostatin LAR in Acromegaly*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3132-3140.	1.8	95
36	Prostatic Hyperplasia: An Unknown Feature of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 775-779.	1.8	94

#	ARTICLE	IF	CITATIONS
37	Somatostatin receptor ligands in the treatment of acromegaly. <i>Pituitary</i> , 2017, 20, 100-108.	1.6	91
38	Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. <i>Clinical Endocrinology</i> , 1997, 47, 23-28.	1.2	89
39	Endoscopic Endonasal Transsphenoidal Approach: An Additional Reason in Support of Surgery in the Management of Pituitary Lesions. <i>Skull Base</i> , 1999, 9, 109-117.	0.4	86
40	T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. <i>Endocrine-Related Cancer</i> , 2016, 23, 871-881.	1.6	82
41	Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. <i>Pituitary</i> , 1999, 1, 115-120.	1.6	81
42	Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors. <i>Endocrine</i> , 2017, 57, 214-219.	1.1	81
43	Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency. <i>European Journal of Endocrinology</i> , 2013, 169, 767-772.	1.9	80
44	Cabergoline plus Lanreotide for Ectopic Cushing's Syndrome. <i>New England Journal of Medicine</i> , 2005, 352, 2457-2458.	13.9	78
45	Rapid Pituitary Tumor Shrinkage with Dissociation between Antiproliferative and Antisecretory Effects of a Long-Acting Octreotide in an Acromegalic Patient. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1592-1599.	1.8	77
46	Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. <i>Endocrine</i> , 2017, 58, 349-359.	1.1	77
47	Interactions between vitamin D and IGF-1: from physiology to clinical practice. <i>Clinical Endocrinology</i> , 2013, 79, 457-463.	1.2	76
48	Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas. <i>Journal of Endocrinological Investigation</i> , 1998, 21, 284-290.	1.8	72
49	Impact of Patient's Age and Disease Duration on Cardiac Performance in Acromegaly: A Radionuclide Angiography Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1518-1523.	1.8	71
50	Reversibility of Joint Thickening in Acromegalic Patients: An Ultrasonography Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2121-2125.	1.8	70
51	Dopamine Receptor Expression and Function in Human Normal Adrenal Gland and Adrenal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4493-4502.	1.8	70
52	High prevalence of vitamin D deficiency and its association with left ventricular dilation: An echocardiography study in elderly patients with chronic heart failure. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 633-640.	1.1	68
53	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1986-1991.	1.8	67
54	Dopamine Receptor Expression and Function in Corticotroph Ectopic Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 65-69.	1.8	67

#	ARTICLE	IF	CITATIONS
55	The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. <i>Journal of Molecular Endocrinology</i> , 2009, 42, 361-370.	1.1	66
56	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , 2017, 176, 453-461.	1.9	66
57	Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 40-47.	1.8	65
58	Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. <i>Clinical Endocrinology</i> , 1999, 51, 611-618.	1.2	64
59	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biotherapy. <i>Neuroendocrinology</i> , 2009, 90, 209-213.	1.2	64
60	Significant tumour shrinkage after 12 months of lanreotide Autogel 120µg treatment given first-line in acromegaly. <i>Clinical Endocrinology</i> , 2009, 71, 237-245.	1.2	64
61	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 817-23.	1.8	64
62	Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor. <i>Neuroendocrinology</i> , 2016, 103, 452-459.	1.2	62
63	Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002, 283, E1056-E1066.	1.8	61
64	Acromegaly is associated with increased cancer risk: a survey in Italy. <i>Endocrine-Related Cancer</i> , 2017, 24, 495-504.	1.6	61
65	Vitamin D and Lung Outcomes in Elderly COVID-19 Patients. <i>Nutrients</i> , 2021, 13, 717.	1.7	61
66	Somatostatin Receptor Subtypes in Human Thymoma and Inhibition of Cell Proliferation by Octreotide in Vitro. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1719-1726.	1.8	59
67	Ultrasound Measurement of Median and Ulnar Nerve Cross-Sectional Area in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 905-909.	1.8	57
68	Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas. <i>Molecular Neurobiology</i> , 2017, 54, 4879-4895.	1.9	57
69	The Association of Fasting Insulin Concentrations and Colonic Neoplasms in Acromegaly: A Colonoscopy-Based Study in 210 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3854-3860.	1.8	56
70	Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 38-43.	1.8	55
71	The Metabolic Profile in Active Acromegaly is Gender-Specific. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E51-E59.	1.8	54
72	β-Arrestin 1 and 2 and G Protein-Coupled Receptor Kinase 2 Expression in Pituitary Adenomas: Role in the Regulation of Response to Somatostatin Analogue Treatment in Patients With Acromegaly. <i>Endocrinology</i> , 2013, 154, 4715-4725.	1.4	54

#	ARTICLE	IF	CITATIONS
73	Managing Cushing's disease: the state of the art. <i>Endocrine</i> , 2014, 47, 9-20.	1.1	54
74	In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2009-2018.	1.8	54
75	Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. <i>Endocrine-Related Cancer</i> , 2014, 21, 691-704.	1.6	53
76	Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with ¹²³ I-methoxybenzamide. <i>Clinical Endocrinology</i> , 2000, 52, 437-445.	1.2	52
77	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. <i>Clinical Endocrinology</i> , 2000, 53, 13-19.	1.2	52
78	Effect of Growth Hormone on Cardiac Function. <i>Hormone Research</i> , 1997, 48, 38-42.	1.8	51
79	Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What's New?. <i>Neuroendocrinology</i> , 2012, 95, 267-276.	1.2	51
80	High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2454-2464.	1.8	51
81	Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. <i>Pituitary</i> , 2008, 11, 93-102.	1.6	50
82	Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. <i>Clinical Endocrinology</i> , 2012, 76, 407-414.	1.2	47
83	Cost-of-illness study in acromegalic patients in Italy. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 1034-1039.	1.8	45
84	Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 289, E1044-E1050.	1.8	44
85	Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 326-31.	1.8	44
86	Orbital Scintigraphy with [¹¹¹ In-Diethylenetriamine Pentaacetic Acid-D-Phe ¹]-Octreotide Predicts the Clinical Response to Corticosteroid Therapy in Patients with Graves' Ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 3790-3794.	1.8	43
87	Neuroendocrine-Immune Interactions: The Role of Cortistatin/Somatostatin System. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 129-144.	1.8	43
88	The pituitary uptake of ¹¹¹ In-DTPA-D-Phe ¹ -octreotide in the normal pituitary and in pituitary adenomas. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 176-183.	1.8	42
89	Normal age-dependent values of serum insulin growth factor-I: Results from a healthy Italian population. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 445-449.	1.8	42
90	Everolimus is an active agent in medullary thyroid cancer: a clinical and <i>in vitro</i> study. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1563-1572.	1.6	42

#	ARTICLE	IF	CITATIONS
91	Cardiovascular aspects in acromegaly: Effects of treatment. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 57-60.	1.5	41
92	Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E165-E172.	1.8	41
93	Somatostatin receptor distribution and function in immune system. <i>Digestive and Liver Disease</i> , 2004, 36, S68-S77.	0.4	40
94	Evidence of Prolonged Orocecal Transit Time and Small Intestinal Bacterial Overgrowth in Acromegalic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2119-2124.	1.8	40
95	Primary empty sella: Why and when to investigate hypothalamic-pituitary function. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 343-346.	1.8	40
96	In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5. <i>Pituitary</i> , 2011, 14, 141-147.	1.6	40
97	Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. <i>European Journal of Endocrinology</i> , 2016, 174, 651-662.	1.9	40
98	Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. <i>Endocrine</i> , 2016, 51, 131-139.	1.1	40
99	Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. <i>Clinical Endocrinology</i> , 2004, 61, 138-144.	1.2	39
100	Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy?. <i>Pituitary</i> , 2015, 18, 583-591.	1.6	39
101	Effect of Two Years of Growth Hormone and Insulin-Like Growth Factor-I Suppression on Prostate Diseases in Acromegalic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3754-3761.	1.8	38
102	Partial visual recovery from radiation-induced optic neuropathy after hyperbaric oxygen therapy in a patient with Cushing disease. <i>European Journal of Endocrinology</i> , 2006, 154, 813-818.	1.9	38
103	Novel chimeric somatostatin analogs: facts and perspectives. <i>European Journal of Endocrinology</i> , 2007, 156, S23-S28.	1.9	38
104	Zebrafish as an innovative model for neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2014, 21, R67-R83.	1.6	38
105	Correlation of Scintigraphic Results Using ¹²³ I-Methoxybenzamide with Hormone Levels and Tumor Size Response to Quinagolide in Patients with Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 248-252.	1.8	36
106	Pegvisomant in acromegaly: Why, when, how. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 693-699.	1.8	35
107	Failure of long-term therapy with sodium valproate in Cushing's disease. <i>Journal of Endocrinological Investigation</i> , 1997, 20, 387-392.	1.8	33
108	Bone mineral density and circulating cytokines in patients with acromegaly. <i>Journal of Endocrinological Investigation</i> , 1998, 21, 688-693.	1.8	33

#	ARTICLE	IF	CITATIONS
109	Escalated-dose somatostatin analogues for antiproliferative effect in CEPNETS: a systematic review. <i>Endocrine</i> , 2017, 57, 366-375.	1.1	33
110	CV 205-502 treatment in therapy-resistant acromegalic patients. <i>European Journal of Endocrinology</i> , 1995, 132, 559-564.	1.9	32
111	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 194-200.	1.8	32
112	Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. <i>Drug Discovery Today</i> , 2014, 19, 458-468.	3.2	31
113	Pharmacotherapy or Surgery as Primary Treatment for Acromegaly?. <i>Drugs and Aging</i> , 2000, 17, 81-92.	1.3	30
114	Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. <i>Endocrine</i> , 2017, 56, 633-638.	1.1	30
115	Effects of a Chronic Treatment with Octreotide in Patients with Functionless Pituitary Adenomas. <i>Hormone Research</i> , 1993, 40, 149-155.	1.8	29
116	In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: Correlation with somatostatin and dopamine D2 receptor scintigraphy. <i>Clinical Endocrinology</i> , 2001, 54, 469-477.	1.2	29
117	Sympathovagal Imbalance in Acromegalic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 115-120.	1.8	29
118	Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. <i>Journal of Endocrinology</i> , 2010, 207, 309-317.	1.2	29
119	Institutional experience of PTH evaluation on fine-needle washing after aspiration biopsy to locate hyperfunctioning parathyroid tissue. <i>Journal of Zhejiang University: Science B</i> , 2009, 10, 323-330.	1.3	28
120	Physiological and pathophysiological role of somatostatin receptors in the human thymus. <i>European Journal of Endocrinology</i> , 2000, 143 Suppl 1, S27-S34.	1.9	27
121	Initial Staging of Lymphoma With Octreotide and Other Receptor Imaging Agents. <i>Seminars in Nuclear Medicine</i> , 2005, 35, 176-185.	2.5	27
122	Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases. <i>Kidney International</i> , 2008, 74, 937-945.	2.6	27
123	Molecular basis of pharmacological therapy in Cushing's disease. <i>Endocrine</i> , 2014, 46, 181-198.	1.1	27
124	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. <i>Oncologist</i> , 2020, 25, 259-265.	1.9	27
125	Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression. <i>Current Molecular Medicine</i> , 2013, 13, 555-571.	0.6	27
126	Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3940.	1.8	26

#	ARTICLE	IF	CITATIONS
127	Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. <i>Endocrine</i> , 2020, 69, 441-450.	1.1	26
128	Positive response to compound CV 205â€“502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. <i>Gynecological Endocrinology</i> , 1994, 8, 175-181.	0.7	25
129	The pathology of the ulnar nerve in acromegaly. <i>European Journal of Endocrinology</i> , 2008, 159, 369-373.	1.9	25
130	Ultrasound of peripheral nerves in acromegaly: changes at 1â€“year followâ€“up. <i>Clinical Endocrinology</i> , 2009, 71, 220-225.	1.2	25
131	Age-related decrease of somatostatin receptor number in the normal human thymus. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2000, 279, E791-E798.	1.8	24
132	Regulation of prostate cancer cell proliferation by somatostatin receptor activation. <i>Molecular and Cellular Endocrinology</i> , 2010, 315, 254-262.	1.6	24
133	Hormone receptors analysis in idiopathic progressive subglottic stenosis. <i>Laryngoscope</i> , 2018, 128, E72-E77.	1.1	24
134	Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. <i>Endocrine</i> , 2018, 61, 533-541.	1.1	24
135	Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?. <i>Oncotarget</i> , 2017, 8, 41044-41063.	0.8	24
136	Identification of a novel mutation in exon 1 ofâ€“androgen receptor gene in an azoospermic patientâ€“with mild androgen insensitivity syndrome: case report and literature review. <i>Fertility and Sterility</i> , 2011, 96, 1165-1169.	0.5	23
137	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. , 0, .		23
138	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2018, 97, 59-61.	1.3	22
139	Comparison among Different Dopamine-Agonists of New Formulation in the Clinical Management of Macroprolactinomas. <i>Hormone Research</i> , 1995, 44, 222-228.	1.8	21
140	Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study. <i>Clinical Endocrinology</i> , 1999, 51, 159-164.	1.2	21
141	Lymphocyte subset pattern in acromegaly. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 125-128.	1.8	21
142	Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas. <i>European Journal of Endocrinology</i> , 2007, 156, S37-S43.	1.9	21
143	Calcitonin assay in wash-out fluid after fine-needle aspiration biopsy in patients with a thyroid nodule and border-line value of the hormone. <i>Journal of Endocrinological Investigation</i> , 2009, 32, 308-312.	1.8	21
144	Pituitary image: pituicytoma. <i>Pituitary</i> , 2015, 18, 592-597.	1.6	21

#	ARTICLE	IF	CITATIONS
145	Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. <i>Endocrine</i> , 2018, 62, 215-233.	1.1	21
146	"Present and future of immunotherapy in Neuroendocrine Tumors". <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 615-636.	2.6	21
147	In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features. <i>Journal of Endocrinological Investigation</i> , 2001, 24, 522-528.	1.8	20
148	Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma. <i>Journal of Zhejiang University: Science B</i> , 2011, 12, 163-173.	1.3	20
149	Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity. <i>Pituitary</i> , 2019, 22, 552-560.	1.6	19
150	Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. <i>Journal of Endocrinology</i> , 1997, 155 Suppl 1, S33-7; discussion S39.	1.2	19
151	Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-16.	0.6	18
152	Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?. <i>Endocrine</i> , 2016, 53, 58-62.	1.1	18
153	KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?. <i>Endocrine</i> , 2017, 57, 494-502.	1.1	18
154	Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 375-385.	1.1	18
155	Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1543-1553.	1.8	18
156	Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet). <i>Journal of Endocrinological Investigation</i> , 2021, 44, 989-994.	1.8	18
157	Cardiac Effect of Thyrotoxicosis in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1426-1432.	1.8	17
158	Computed Tomography Colonography in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 218-222.	1.8	17
159	Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives. <i>Annales D'Endocrinologie</i> , 2015, 76, 43-58.	0.6	17
160	Sonographic Depiction of Trigger Fingers in Acromegaly. <i>Journal of Ultrasound in Medicine</i> , 2009, 28, 1441-1446.	0.8	16
161	Ectopic Cushing and Other Paraneoplastic Syndromes in Thoracic Neuroendocrine Tumors. <i>Thoracic Surgery Clinics</i> , 2014, 24, 277-283.	0.4	16
162	Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2019, 20, 365-381.	2.6	16

#	ARTICLE	IF	CITATIONS
163	Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells. <i>Pituitary</i> , 2019, 22, 89-99.	1.6	16
164	<p>Octreotide-Resistant Acromegaly: Challenges and Solutions</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 379-391.	0.9	16
165	Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective. <i>Frontiers in Endocrinology</i> , 2021, 12, 677919.	1.5	16
166	Metabolic and cardiovascular risk in patients with a history of differentiated thyroid carcinoma: A case-controlled cohort study. <i>Thyroid Research</i> , 2008, 1, 2.	0.7	15
167	Leptin, Ghrelin, and Adiponectin Evaluation in Transsexual Subjects During Hormonal Treatments. <i>Journal of Andrology</i> , 2008, 29, 580-585.	2.0	15
168	Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients. <i>European Journal of Endocrinology</i> , 2014, 170, 247-254.	1.9	15
169	Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: Effect of mono- and bi-specific somatostatin analogs on cell growth. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 860-870.	1.6	15
170	Role of Dopamine Receptors in Normal and Tumoral Pituitary Corticotrophic Cells and Adrenal Cells. <i>Neuroendocrinology</i> , 2010, 92, 17-22.	1.2	14
171	PRRT: identikit of the perfect patient. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 563-579.	2.6	14
172	Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. <i>Clinical Endocrinology</i> , 1998, 49, 77-84.	1.2	13
173	Musculoskeletal complications of acromegaly: what radiologists should know about early manifestations. <i>Radiologia Medica</i> , 2011, 116, 781-792.	4.7	13
174	Somatostatin receptor scintigraphy in thoracic diseases. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 889-902.	1.8	12
175	Pre-surgical treatment with somatostatin analogues in patients with acromegaly: The case for. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 613-615.	1.8	12
176	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. <i>Digestive and Liver Disease</i> , 2021, 53, 367-374.	0.4	12
177	Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 789-801.	1.8	12
178	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. <i>European Journal of Cancer</i> , 2021, 144, 200-214.	1.3	12
179	Vasopressin levels in Cushing's disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing's disease. <i>Clinical Endocrinology</i> , 1996, 45, 157-166.	1.2	11
180	Fixity of vocal cords and laryngocele in acromegaly. <i>Journal of Endocrinological Investigation</i> , 1997, 20, 672-674.	1.8	11

#	ARTICLE	IF	CITATIONS
181	Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 166-169.	1.8	11
182	Increased mammographic breast density in acromegaly: quantitative and qualitative assessment. <i>European Journal of Endocrinology</i> , 2011, 164, 335-340.	1.9	11
183	Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. <i>Clinical Endocrinology</i> , 2013, 79, 211-216.	1.2	11
184	Rare diseases in clinical endocrinology: a taxonomic classification system. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 193-259.	1.8	11
185	Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center. <i>Endocrine</i> , 2016, 51, 524-533.	1.1	11
186	One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients. <i>Endocrine</i> , 2017, 55, 573-581.	1.1	11
187	Hypothalamic-Pituitary-Adrenal Axis in Neuropsychiatric Disorders. <i>Annals of the New York Academy of Sciences</i> , 1994, 741, 263-270.	1.8	11
188	Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 528-34.	1.8	11
189	Technetium-99m penta-valent dimer-captosuccinic acid imaging in patients with pituitary adenomas. <i>European Journal of Endocrinology</i> , 1995, 133, 38-47.	1.9	10
190	Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas. <i>European Journal of Endocrinology</i> , 1995, 133, 189-194.	1.9	10
191	Neuroendocrine aspects of immunolymphoproliferative diseases. <i>Annals of Oncology</i> , 2001, 12, S125-S130.	0.6	10
192	Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life. <i>Endocrine</i> , 2022, 77, 510-518.	1.1	10
193	Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies. <i>European Journal of Endocrinology</i> , 1994, 131, 14-19.	1.9	9
194	Tumor Necrosis Factor-Alpha Increases after Corticotropin-Releasing Hormone Administration in Cushing's Disease. <i>Neuroendocrinology</i> , 1996, 64, 393-397.	1.2	9
195	In Vivo and In Vitro Detection of Dopamine D2 Receptors in Uveal Melanomas. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 895-902.	0.7	9
196	Serum osteoprotegerin and soluble receptor activator of nuclear factor κ B ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study. <i>Metabolism: Clinical and Experimental</i> , 2007, 56, 699-707.	1.5	9
197	Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS). <i>Journal of Endocrinological Investigation</i> , 2018, 41, 1259-1266.	1.8	9
198	Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease. <i>European Journal of Endocrinology</i> , 2000, 143 Suppl 1, S35-S42.	1.9	8

#	ARTICLE	IF	CITATIONS
199	The role of somatostatin receptors in the medical treatment of acromegaly. Digestive and Liver Disease, 2004, 36, S55-S59.	0.4	8
200	Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience. Pituitary, 2012, 15, 215-221.	1.6	8
201	Diabetic Hepatosclerosis Presenting With Severe Cholestasis. Diabetes Care, 2013, 36, e206-e206.	4.3	8
202	Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins. Endocrine, 2016, 53, 551-557.	1.1	8
203	Potential indications for somatostatin analogues: immune system and lymphoproliferative disorders. Journal of Endocrinological Investigation, 2005, 28, 111-7.	1.8	8
204	Impaired luteinizing hormone responsiveness to gonadotropin-releasing hormone in the inferior petrosal sinuses of hyperprolactinemic patients. Gynecological Endocrinology, 1995, 9, 15-21.	0.7	7
205	Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. Clinical Endocrinology, 2001, 54, 97-106.	1.2	7
206	99m Technetium penta-valent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. Clinical Endocrinology, 2002, 56, 713-721.	1.2	7
207	2. Somatostatin and dopamine receptors. Tumori, 2010, 96, 802-805.	0.6	7
208	Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data. Pituitary, 2012, 15, 209-214.	1.6	7
209	Somatostatin receptor expression in thymic tumors. Frontiers in Bioscience - Landmark, 2009, Volume, 3304.	3.0	7
210	Current diagnostic guidelines for biochemical diagnosis of acromegaly. Minerva Endocrinologica, 2004, 29, 207-23.	1.7	7
211	Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. Cancers, 2022, 14, 2501.	1.7	7
212	Height, weight, height velocity of primary school population sample in Campania region. Journal of Endocrinological Investigation, 1998, 21, 142-147.	1.8	6
213	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. Journal of Nuclear Medicine, 2020, 61, 1094-1095.	2.8	6
214	GH Replacement in the Elderly: Is It Worth It?. Frontiers in Endocrinology, 2021, 12, 680579.	1.5	6
215	Title is missing!. Annals of Oncology, 2001, 12, 125-130.	0.6	6
216	Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature. Journal of Endocrinological Investigation, 2022, 45, 1465-1481.	1.8	6

#	ARTICLE	IF	CITATIONS
217	Replacement therapy and cardiovascular diseases. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 85-90.	1.8	6
218	Corticotropin Releasing Hormone Administration Increases Alpha-Melanocyte-Stimulating Hormone Levels in the Inferior Petrosal Sinuses in a Subset of Patients with Cushing's Disease. <i>Hormone Research</i> , 1996, 46, 26-32.	1.8	5
219	Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients. <i>Clinical Endocrinology</i> , 2005, 63, 294-297.	1.2	5
220	Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 669-678.	1.8	5
221	Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST2 in Mediating Ligand Effects. <i>Cancers</i> , 2021, 13, 1816.	1.7	5
222	The effect of sodium restriction on iodine prophylaxis: a review. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1121-1138.	1.8	5
223	Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing's disease before and after corticotropin-releasing hormone administration. <i>Journal of Endocrinological Investigation</i> , 1998, 21, 257-262.	1.8	4
224	Sympathovagal imbalance in transsexual subjects. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 1014-1019.	1.8	4
225	Effect of environment on growth: Auxological and hormonal parameters in African and Italian children. <i>Growth Hormone and IGF Research</i> , 2009, 19, 238-241.	0.5	4
226	Autonomic nervous system and cardiovascular risk assessment during one year of growth hormone (GH) replacement therapy in adults with GH deficiency. <i>Hormones</i> , 2014, 14, 134-41.	0.9	4
227	Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. <i>Archives of Endocrinology and Metabolism</i> , 2015, 59, 554-558.	0.3	4
228	Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 1265-1269.	1.8	4
229	Adult iatrogenic Cushing's syndrome induced by topical skin corticosteroid misuse. <i>Therapie</i> , 2019, 74, 547-549.	0.6	4
230	Efficacy of a novel second-generation somatostatin-dopamine chimera (TBR-065) in human medullary thyroid cancer: a preclinical study. <i>Neuroendocrinology</i> , 2020, 111, 937-950.	1.2	4
231	Safety and effectiveness of Omnitrope® in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 327-337.	1.8	4
232	A comparative cross-sectional study on sleep quality in patients with a history of differentiated thyroid carcinoma and its correlation with quality of life. <i>Endocrine</i> , 2021, 73, 347-357.	1.1	4
233	Acromegaly Management in a Tertiary Referral Center After 1 Year of the Coronavirus 2019 Pandemic: A Double Challenge. <i>Endocrine Practice</i> , 2021, 27, 856-857.	1.1	4
234	Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length. <i>Pituitary</i> , 2022, 25, 246-257.	1.6	4

#	ARTICLE	IF	CITATIONS
235	Somatostatin receptors in the thymus. <i>Annals of Medicine</i> , 1999, 31 Suppl 2, 28-33.	1.5	4
236	Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study. <i>European Journal of Endocrinology</i> , 2022, , .	1.9	4
237	Different sensitivity to sodium valproate in healthy, non-tumoral and tumoral hyperprolactinemic subjects. <i>Journal of Endocrinological Investigation</i> , 1997, 20, 513-518.	1.8	3
238	Acromegaly and immune function. <i>NeuroImmune Biology</i> , 2002, , 247-257.	0.2	3
239	Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 352-359.	1.8	3
240	Somatostatin receptor pathophysiology in the neuroendocrine system. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 149-157.	1.2	3
241	Diabetes Secondary to Neuroendocrine Gastroenteropancreatic Tumors. <i>Frontiers in Diabetes</i> , 2014, , 64-76.	0.4	3
242	Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (Hypo<scp>CCS</scp>) according to tertiles of growth hormone peak concentration following stimulation testing at study entry. <i>Clinical Endocrinology</i> , 2015, 83, 527-535.	1.2	3
243	Further Evaluation of IGF-I Responsiveness to ACTH in Children Affected with IGHD. <i>Hormone Research</i> , 1992, 38, 150-153.	1.8	2
244	Acute administration of hexarelin stimulates GH secretion during day and night in normal men. <i>Clinical Endocrinology</i> , 1997, 46, 275-279.	1.2	2
245	Hormone and Receptor Candidates for Target and Biotherapy of Neuroendocrine Tumors. <i>Frontiers of Hormone Research</i> , 2015, 44, 216-238.	1.0	2
246	The role of somatostatin and somatostatin analogs in the pathophysiology of the human immune system. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 94-102.	1.8	2
247	The role of somatostatin analogs in the management of immunoproliferative disease. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 103-8.	1.8	2
248	Comparative Diagnostic Performance of a Novel Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) Kit for the Rapid Detection of SARS-CoV-2. <i>Pathogens</i> , 2021, 10, 1629.	1.2	2
249	Lack of Somatostatin Analogs Effectiveness in Gonadotropin-Secreting Pituitary Adenomas. , 2006, 16, 208-213.		1
250	Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 389-393.	1.8	1
251	Emerging drugs for the treatment of acromegaly. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 409-417.	1.0	1
252	The primary role of radiological imaging in the diagnosis of rare musculoskeletal diseases. Emphasis on ultrasound. <i>Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ-SzopiÅska</i> , 2019, 19, 187-192.	0.7	1

#	ARTICLE	IF	CITATIONS
253	Somatostatin and dopamine receptors. Tumori, 2010, 96, 802-5.	0.6	1
254	Methodology of the SORENTO clinical trial: Assessing the efficacy and safety of high exposure octreotide subcutaneous depot in patients with GEP-NETs.. Journal of Clinical Oncology, 2022, 40, TPS4178-TPS4178.	0.8	1
255	Prostatic Hyperplasia: An Unknown Feature of Acromegaly. Journal of Urology, 1998, 160, 1583-1584.	0.2	0
256	A Unique Association of Clinical "Persistent Mullerian Duct Syndrome" and Syringoid Carcinoma of the Perineal-Scrotal Skin: A Consequence of Urologic Surgery?. Journal of Andrology, 2008, 29, 15-19.	2.0	0
257	Chapter 8 Autoimmunity and the Pituitary Gland. Handbook of Systemic Autoimmune Diseases, 2008, 9, 83-93.	0.1	0
258	Le terapie combinate nell'acromegalia: pro e contro. L Endocrinologo, 2013, 14, 71-78.	0.0	0
259	In memory of Francesco Maria Minuto. Growth Hormone and IGF Research, 2014, 24, 155-156.	0.5	0
260	Neuroendocrine Tumours: Diagnosis, Therapy and Follow-up. , 2018, , 203-222.		0
261	Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. Expert Opinion on Pharmacotherapy, 2020, 21, 2317-2324.	0.9	0
262	Somatostatin Control of Immune Functions. , 2004, , 193-206.		0
263	Italian Society of Endocrinology Career Award Lecture: from somatostatin to somatomedin. Journal of Endocrinological Investigation, 2012, 35, 869-74.	1.8	0